Labiana Health

Labiana Health Net Tangible Assets

The Net Tangible Assets of Labiana Health (LAB.MC) as of Nov 19, 2026 is 5.08 M EUR. In the previous year, Net Tangible Assets was -3.16 M EUR — a change of -260.99% (higher).

Net Tangible Assets

5.08 MEUR

YoY

-260.99%

Last updated:

Net Tangible Assets of Labiana Health is 2025 5.08 M EUR. Net Tangible Assets of Labiana Health was 2024 -3.16 M EUR. It decreases by -260.99% higher compared to the previous year.

The Labiana Health Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2018
844,300.00 EUR
Jan 1, 2019
-686,600.00 EUR
Jan 1, 2021
10.31 M EUR
Jan 1, 2022
-1.30 M EUR
Jan 1, 2023
-4.10 M EUR
Jan 1, 2024
-3.16 M EUR
Jan 1, 2025
5.08 M EUR
The Labiana Health Net Tangible Assets history
YEARNet Tangible AssetsYoY
5.08 MEUR-260.99%
-3.16 MEUR-22.93%
-4.10 MEUR+214.77%
-1.30 MEUR-112.62%
10.31 MEUR-1,601.73%
-686,600.00EUR-181.32%
844,300.00EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Labiana Health Stock analysis

What does Labiana Health do? Labiana Health SA generates revenue through the development, manufacturing, and marketing of animal and human medicines. The company focuses on drug research and development, including galenic and analytical development, as well as drug manufacturing, which encompasses formulation development and bacterial vaccine manufacturing. Regulatory services for pharmaceutical product registration in global markets also contribute to its income. Its subsidiaries operate in Ecuador, Mexico, Serbia, and Turkey, serving markets for both animal and human pharmaceutical products. The company's primary products include sterile and lyophilized dosage forms, which are manufactured for use in animal and human medicine. These products are sold to customers in the pharmaceutical industry, including distributors and healthcare providers in the regions where Labiana Health SA has a presence. The company’s R&D and manufacturing capabilities support the production of medicines that meet regulatory standards for global markets. Labiana Health SA’s business model relies on its subsidiaries in Ecuador, Mexico, Serbia, and Turkey to facilitate market access and distribution. The company’s revenue streams are derived from the sale of pharmaceutical products, regulatory services, and the development of new drug formulations. Its focus on sterile and lyophilized dosage forms positions it within the specialized pharmaceutical manufacturing sector, targeting both animal and human medicine segments. Labiana Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labiana Health stock

Net Tangible Assets of Labiana Health is 5.08 M EUR in 2025.

Net Tangible Assets of Labiana Health changed from -3.16 M EUR to 5.08 M EUR, representing a -260.99% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets Labiana Health since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's Labiana Health historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Labiana Health

All Key Metrics — Labiana Health